XML 16 R5.htm IDEA: XBRL DOCUMENT v3.21.1
Consolidated Statements of Changes in Stockholders’ Equity (unaudited) - USD ($)
Series 1 Convertible Preferred Stock
Series 2 Convertible Preferred Stock
Common Stock
Additional Paid in Capital
Accumulated Deficit
Total
Balance at Dec. 31, 2019 $ 855,955 $ 21,952,000 $ 1,779 $ 35,313,721 $ (48,155,180) $ 9,968,275
Balance (in Shares) at Dec. 31, 2019 171,191 21,952 17,783,960      
Provision for compensation expense related to stock options       171,815   171,815
Issuance of warrants in connection with consulting agreement       43,999   43,999
Exercise of warrants into common stock     $ 10 131,240   13,250
Exercise of warrants into common stock (in Shares)     105,000      
Exchange offer of warrants     $ 346 (346)    
Exchange offer of warrants (in Shares)     3,462,683      
Net income         51,685 51,685
Balance at Mar. 31, 2020 $ 855,955 $ 21,952,000 $ 2,135 35,660,429 (48,103,495) 10,367,024
Balance (in Shares) at Mar. 31, 2020 171,191 21,952 21,351,643      
Balance at Dec. 31, 2020 $ 851,660 $ 21,952,000 $ 2,136 36,843,326 (48,495,076) 11,154,046
Balance (in Shares) at Dec. 31, 2020 170,332 21,952 21,359,945      
Provision for compensation expense related to stock options       380,263   380,263
Issuance of warrants in connection with consulting agreement 212,923 212,923
Issuance of warrants in connection with consulting agreement (in Shares)      
Exercise of stock options into common stock $ 2 12,910 $ 12,912
Exercise of stock options into common stock (in Shares) 16,000     16,000
Net income         1,237 $ 1,237
Balance at Mar. 31, 2021 $ 851,660 $ 21,952,000 $ 2,138 $ 37,449,422 $ (48,493,839) $ 11,761,381
Balance (in Shares) at Mar. 31, 2021 170,332 21,952 21,375,945